Market eyes CAR-T pricing as China grants second approval in September
Danni Yin · 10/22/2021
Chinese regulators gave their nod to the second domestic CAR-T cell therapy in three months, raising concerns in the market about how companies will make these expensive, advanced treatments more accessible to Chinese patients. The PD-1 frenzy also continued with PD-1 biosimilars.
Yizhong launches $160M IPO on STAR to bring paclitaxel micelles to market
Elise Mak · 09/10/2021
Backed by Sinolink Securities, the company issued 26.45 million shares at RMB38.1 apiece.
Copyright © 2016-2021 PharmaDJ .All Rights Reserved.   Suggestions and feedback:   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement